KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission

by Kelli L. Kuhen, Arnab K. Chatterjee, Matthias Rottmann, Kerstin Gagaring, Rachel Borboa, Jennifer Buenviaje, Zhong Chen, Carolyn Francek, Tao Wu, Advait Nagle, S. Whitney Barnes, David Plouffe, Marcus C.S. Lee, David A. Fidock, Wouter Graumans, Marga Van De Vegte-Bolmer, Geert J. Van Gemert, Grennady Wirjanata, Boni Sebayang, Jutta Marfurt, Bruce Russell, Rossarin Suwanarusk, Ric N. Price, Francois Nosten, Anchalee Tungtaeng, Montip Gettayacamin, Jetsumon Sattabongkot, Jennifer Taylor, John R. Walker, David Tully, Kailash P. Patra, Erika L. Flannery, Joseph M. Vinetz, Laurent Renia, Robert W. Sauerwein, Elizabeth A. Winzeler, Richard J. Glynne, Thierry T. Diagana
Published 2018

Targeting Plasmodium PI(4)K to eliminate malaria

by Case W. McNamara, Marcus C.S. Lee, Chek Shik Lim, Siau Hoi Lim, Jason Roland, Advait Nagle, Oliver Simon, Bryan K.S. Yeung, Arnab K. Chatterjee, Susan L. McCormack, Micah J. Manary, Anne Marie Zeeman, Koen J. Dechering, T. R.Santha Kumar, Philipp P. Henrich, Kerstin Gagaring, Maureen Ibanez, Nobutaka Kato, Kelli L. Kuhen, Christoph Fischli, Matthias Rottmann, David M. Plouffe, Badry Bursulaya, Stephan Meister, Lucia Rameh, Joerg Trappe, Dorothea Haasen, Martijn Timmerman, Robert W. Sauerwein, Rossarin Suwanarusk, Bruce Russell, Laurent Renia, Francois Nosten, David C. Tully, Clemens H.M. Kocken, Richard J. Glynne, Christophe Bodenreider, David A. Fidock, Thierry T. Diagana, Elizabeth A. Winzeler
Published 2018